Aiforia, a Helsinki, Finland-based provider of AI-based solutions for clinical and preclinical image analysis in pathology, raised €25.2M in Series B funding.
The round was led by Epredia, a subsidiary of PHC Holdings Corporation, with participation from Aktia Nordic Micro Cap and existing shareholders.
The company intends to use the funds to strengthen its global presence for pharmaceutical companies as well as develop and release new platforms for the diagnosis of the most common cancers in the world.
Led by Jukka Tapaninen, CEO, Aiforia equips pathologists and scientists in preclinical, university and clinical laboratories with deep learning artificial intelligence and cloud-based technology to increase the speed, precision and consistency of image analysis large and complex medical devices in various fields, from oncology to neuroscience.
Aiforia Clinical Suites are tool portfolios that enable pathologists and hospitals to harness the power of AI to speed up specimen examination, improve diagnostic accuracy, and improve outcomes for the patients. Breast and lung cancer suites are to be CE-IVD marked and launched this year.
They are currently used by over 3,000 users in over 50 countries.